300676 BGI Genomics
- 41.46
- -0.34-0.81%
BGI Genomics News
BGI-HL OHA Lab Inaugurated in Harbin, Initiating Colorectal Cancer Risk Assessment for 800,000
SHENZHEN, China, May 13, 2024 /PRNewswire/ -- On May 10, 2024, the BGI-Heilongjiang Omics Health Axis Intelligent Laboratory (BGI-HL OHA Intelligent Laboratory) was inaugurated in Harbin, Heilongjian
There May Be Reason For Hope In BGI Genomics' (SZSE:300676) Disappointing Earnings
Shareholders appeared unconcerned with BGI Genomics Co., Ltd.'s (SZSE:300676) lackluster earnings report last week. Our analysis suggests that while the profits are soft, the foundations of the busin
BGI Genomics Co., Ltd.'s (SZSE:300676) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 3.8x BGI Genomics Co., Ltd. (SZSE:300676) is a stock worth checking out, seeing as almost half of all the Biotechs companies in China have
Building a Better Future: NJ Roofing Companies Partner With BGI to Empower Communities
CARLSTADT, N.J., April 5, 2024 /PRNewswire/ -- In a testament to the power of community and shared purpose, a collective of New Jersey roofing companies has announced a unique partnership with Busine
Next Generation Sequencing Market Size Is Set to Grow by USD 3409.76 Million From 2023-2027, 10X Genomics Inc., Azenta Inc. & BGI Genomics Co. Ltd., and More to Emerge as Some of the Key Vendors, Technavio
The global next generation sequencing market size is estimated to grow by USD 3409.76 million from 2023 to 2027, according to Technavio. The market...
Is BGI Genomics (SZSE:300676) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems
Uniting for Women's Wellness on IWD - From China to Uzbekistan
2024 Financial Report | BGI's profit fell by more than 80%, making it difficult to find the next outlet
The era of gold everywhere is over
Huada Gene (300676.SZ) net profit of 91.121 million yuan in 2023 decreased by 88.64% year on year
Huada Gene (300676.SZ) released its 2023 annual performance report. During the reporting period, the company is expected to operate...
Huada Gene (300676.SZ): Chromosomal aneuploidy and fragment deletion testing products obtained medical device registration certificates
Huada Gene (300676.SZ) issued an announcement. Huada Biotechnology (Wuhan) Co., Ltd., a wholly-owned subsidiary of the company...
Are BGI Genomics Co., Ltd.'s (SZSE:300676) Mixed Financials Driving The Negative Sentiment?
BGI Genomics (SZSE:300676) has had a rough three months with its share price down 17%. It seems that the market might have completely ignored the positive aspects of the company's fundamentals and d
Investors in BGI Genomics (SZSE:300676) Have Unfortunately Lost 73% Over the Last Three Years
As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an overall portfolio. So spare a thought for the long term shareholders of BGI Genomics
China Investment Securities: Domestic IVD accelerates overseas expansion to build a second growth engine
With the advancement of policies such as collection, domestic brands are expected to accelerate the increase in domestic market share. From a longer-term perspective, fully entering overseas markets is a necessary step for the domestic IVD industry to further open up room for growth and extend the stage of rapid development.
Improved Revenues Required Before BGI Genomics Co., Ltd. (SZSE:300676) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 3.5x BGI Genomics Co., Ltd. (SZSE:300676) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in China hav
Huada Gene (300676.SZ): Huada Digital Human Fecal DNA Methylation Testing Product Obtains Medical Device Registration Certificate
Glonghui December 18丨Huada Gene (300676.SZ) announced that the SDC2, ADHFE1, and PPP2R5C gene methylation joint test kit for human SDC2,, and PPP2R5C gene methylation, a wholly-owned subsidiary of the company, recently obtained a medical device registration certificate issued by the State Drug Administration. The kit products approved this time are used to qualitatively detect the methylation of SDC2, ADHFE1, and PPP2R5C genes in intestinal exfoliated cells in human stool samples in vitro. The kit is based on a fluorescence quantitative PCR detection platform and has bowel cancer and an advanced stage
Huada CEO Yin Yefa took a group photo with Dong Yuhui and Yu Minhong and called them the best men in China
On the evening of December 16, Sina Technology News reported that BGI CEO Yin Ye posted a group photo with Yu Minhong, founder of Oriental Selection, and Dong Yuhui, anchor of Oriental Selection, with a caption saying, “There is calm every time big things come, and I don't believe there are any ancient virtues now. I'm optimistic about you guys, the best men in China. Previously, Yin Ye had a conversation with Dong Yuhui as a guest on the live broadcast room selected by Oriental, and she also had many conversations with Yu Minhong on topics such as books and life.
These 4 Measures Indicate That BGI Genomics (SZSE:300676) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
BGI (300676.SZ) granted 1.4 million restricted shares to 18 incentive recipients
Huada Gene (300676.SZ) issued an announcement, and the company reviewed and approved “On Restricted Stocks to 2022...
Ping An Securities: Breakthrough in Alzheimer's disease targeting Abeta treatment drugs is expected to stimulate potential demand at both ends of diagnosis and treatment
The number of AD cases continues to increase, bringing huge social burdens. The rise of Abeta drugs is of epoch-making significance.
BGI Genomics Co., Ltd.'s (SZSE:300676) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Most readers would already be aware that BGI Genomics' (SZSE:300676) stock increased significantly by 8.8% over the past month. But the company's key financial indicators appear to be differing acro
Analysis
Price Target
No Data
